Why AbCellera Biologics Inc.’s (ABCL) Stock Is Down 7.15%
As of Friday, October 30, AbCellera Biologics Inc.’s ABCL share price has dipped by 7.15%, which has investors questioning if this is right time to buy.Michael Rose
Stock Evaluator: AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. ABCL
$12.27
-0.81
-6.19%
October 30, 2026 4:00:00 PM
EST
Volume: 3,874,573
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Commentary & Analysis
Why AbCellera Biologics Inc.’s (ABCL) Stock Is Down 5.32%
As of Friday, October 16, AbCellera Biologics Inc.’s ABCL share price has dipped by 5.32%, which has investors questioning if this is right time to buy.Jenna Brashear
Why AbCellera Biologics Inc.’s (ABCL) Stock Is Down 5.38%
As of Thursday, October 08, AbCellera Biologics Inc.’s ABCL share price has dipped by 5.38%, which has investors questioning if this is right time to buy.Michael Rose
Which Is a Better Investment, AbCellera Biologics Inc. or Fortrea Holdings Inc. Stock?
Learn more about whether AbCellera Biologics Inc. or Fortrea Holdings Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Why AbCellera Biologics Inc.’s (ABCL) Stock Is Up 10.84%
As of Thursday, September 17, AbCellera Biologics Inc.’s ABCL share price has surged by 10.84%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | ABCL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4,238.5 | $3,634.1 | 65% |
|
| Shares Out (Mil) | 305.6 | 105.4 | 83% |
|
| Institutional Ownership | 54.6% | 88.3% | 37% |
|
| Float (Mil) | 220.9 | 79.7 | 75% |
|
| Beta | 1.41 | 1.19 | 80% |
|
| Avg Daily Volume (000s) | 3,416 | 952 | 89% |
|
| Price Change (52-week) |
132.3% | 90.7% | 97% |
|
| Growth | ABCL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (20.3%) | 7.6% | 2% |
|
| Net Income (5yr) | (26.4%) | (11.2%) | 16% |
|
| EPS (5yr) | (25.3%) | 2.5% | 10 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.1%) | (15.0%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 8 | 7 | |
| Current EPS | ($0.178) | ($0.674) | ($0.763) | |
| Month Ago EPS | ($0.170) | ($0.668) | ($0.764) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.175) | ($0.650) | ($0.720) | |
| Year/Year Chg | (1.7%) | 37.6% | 75.3% | |
| Financials | ABCL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $66 | $800 | 23% |
|
| Net Income (TTM) (Mil) | ($165) | ($31) | 8% |
|
| EPS (TTM) | ($0.546) | ($0.300) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($95) | $47 | 6% |
|
| Net Cash Flow (TTM) (Mil) | $27 | $21 | 65% |
|
| Long-Term Debt (Q1) (Mil) | $130 | $284 | 46% |
|
| Enterprise Value (Q1) (Mil) | $3,426 | $3,582 | 57% |
|
| Valuation | ABCL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.48 | 3.67 | 77% |
|
| P/E | na | 39.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 6.8 | na |
|
| Ratios | ABCL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (198.9%) | 47.7% | 1% |
|
| Net Margin | (248.8%) | (2.6%) | 4% |
|
| ROA | (12.2%) | (4.3%) | 24% |
|
| ROE | (17.3%) | (7.7%) | 24% |
|
| Liabilities to Assets | 31.5% | 41.8% | 23% |
|
| F-Score | 5 | 5 | 51% |
|
AbCellera Biologics Inc. did not pass any screens on 10/29/2026.
